Clinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy—A systematic review based on a subgroup analysis

Abstract

Ethnopharmacological relevanceThe purpose of this study is to systematically evaluate the efficacy of traditional Chinese medicine (TCM) decoctions with different ingredients in the treatment of diabetic nephropathy (DN). Materials and methodsPapers obtained after the retrieval of randomized controlled clinical trials (RCTs) of TCM treatments of diabetic nephropathy through online database (e.g. Medline, CBM, CNKI, VIP, the online database of Chinese medicine, CDFD, CMFD, and CENTRAL FROM Cochrane Library, etc.) as well as research data in our library. They were published between January 2001 and December 2012. According to the categories of the main TCM ingredients, all the cases in the literature were divided into a liver–kidney YIN deficiency group, a QI-BLOOD YIN-and-YANG deficiency group, and a spleen–kidney YANG deficiency group. Stata 11.0 was applied for subgroup analysis. ResultsA total of 21 Chinese RCTs were included in this review. The Q values of the three groups were 13.18, 0.25 and 3.27, respectively, P>0.05, and thus, there was no clinical heterogeneity. The combined relative risk (RR) value and its 95% confidence interval were 1.48 (1.37, 1.60), 1.19 (1.06, 1.34), and 1.33 (1.19, 1.50), respectively, P<0.05. ConclusionsCompared with the qi-blood yin-and-yang deficiency group and the spleen–kidney yang deficiency group, the liver–kidney yin deficiency group has better prospects in clinical application to ensure renal function during the treatment of DN, and this possibility is worthy of further study.